Institutional shares held 24.5 Million
40.3K calls
400 puts
Total value of holdings $203M
$333K calls
$3K puts
Market Cap $355M
43,719,500 Shares Out.
Institutional ownership 56.02%
# of Institutions 106


Latest Institutional Activity in YMAB

Top Purchases

Q3 2024
Logos Global Management LP Shares Held: 800K ($6.49M)
Q3 2024
State Street Corp Shares Held: 1.21M ($9.81M)
Q3 2024
Paradigm Biocapital Advisors LP Shares Held: 4.09M ($33.1M)
Q3 2024
Boothbay Fund Management, LLC Shares Held: 557K ($4.52M)
Q3 2024
Goldman Sachs Group Inc Shares Held: 223K ($1.81M)

Top Sells

Q3 2024
Millennium Management LLC Shares Held: 71.6K ($581K)
Q3 2024
Point72 Asset Management, L.P. Shares Held: 95.4K ($774K)
Q3 2024
Soleus Capital Management, L.P. Shares Held: 400K ($3.24M)
Q3 2024
Acadian Asset Management LLC Shares Held: 106K ($858K)
Q3 2024
D. E. Shaw & Co., Inc. Shares Held: 788K ($6.39M)

About YMAB

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.


Insider Transactions at YMAB

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
369K Shares
From 18 Insiders
Grant, award, or other acquisition 237K shares
Exercise of conversion of derivative security 133K shares
Sell / Disposition
320K Shares
From 7 Insiders
Open market or private sale 320K shares

Track Institutional and Insider Activities on YMAB

Follow Y-mAbs Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells YMAB shares.

Notify only if

Insider Trading

Get notified when an Y M Abs Therapeutics, Inc. insider buys or sells YMAB shares.

Notify only if

News

Receive news related to Y-mAbs Therapeutics, Inc.

Track Activities on YMAB